Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 12,898	$ 5,652
Sales and marketing	1,501	512
General and administrative	7,789	2,120
Total operating expenses	22,188	8,284
Loss from operations	(22,188)	(8,284)
Other income (expenses), net:
Interest expense, net	(29)	(57)
Gain (loss) on revaluation of warrant liabilities	15,664	(8,426)
Loss on revaluation of derivative liabilities	0	(138,141)
Gain on revaluation of earnout liabilities	840	0
Other income (expense), net	4	(10)
Total other income (expenses), net	16,479	(146,634)
Net loss to common stockholders	$ (5,709)	$ (154,918)
Net loss per share, basic (in USD per share)	$ (0.04)	$ (2.51)
Net loss per share, diluted (in USD per share)	$ (0.04)	$ (2.51)
Weighted average shares used in per share calculation, basic (in shares)	151,683,819	61,693,067
Weighted average shares used in per share calculation, diluted (in shares)	151,683,819	61,693,067